Abstract
Objective: Investigating BRCA mutational status in ovarian cancer patients has a key role, both to identify hereditary cancer predisposition and to address therapeutic choices. Approximately 20–25% of patients with high-grade serous ovarian cancers (HGSOC) present with a germline BRCA1/2 mutation, but a further 5–7% of patients will have a somatic BRCA1/2 mutation, which might be missed if tumor genomic profile is not performed. The objective of this prospective study is to investigate the feasibility and reliability of a BRCA screening workflow based on tumor-tissue BRCA analysis and secondary germline screening, in a tertiary referral center.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
